Previous close | 3.8000 |
Open | 3.8000 |
Bid | 3.6500 |
Ask | 3.9500 |
Strike | 440.00 |
Expiry date | 2024-01-19 |
Day's range | 3.8000 - 3.8000 |
Contract range | N/A |
Volume | |
Open interest | 794 |
(Bloomberg) -- The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.Most Read from BloombergWells Fargo Preps for Wealth Battle After $1 Billion TurnaroundUS to Keep a Distance From India-Canada Dispute, Signum’s Myers SaysChina’s Ultra-Rich Gen Zs Flock Home as Global Tensions RiseRaw Meat-Eating Liver King And Other Health Influencers Face Mounting Lawsuit
Based on analysts' projections, you might think the pharmaceutical giant isn't worth investing in right now.
Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.